Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CINC CinCor Pharma (CINC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About CinCor Pharma Stock (NASDAQ:CINC) 30 days 90 days 365 days Advanced Chart Ad Desko DigitalCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD! Get Your FREE Gold Investor Kit NOW! Get CinCor Pharma alerts:Sign Up Key Stats Today's Range$29.02▼$29.3550-Day Range$28.73▼$29.5652-Week Range$10.53▼$43.15Volume6.35 million shsAverage Volume818,447 shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.Read More… Central Bank Abandons USD (Ad)You know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD! Get Your FREE Gold Investor Kit NOW! Receive CINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CinCor Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CINC Stock News HeadlinesCinRx Pharma portfolio company CinDome raises $40M toward Series B roundMay 28, 2024 | bizjournals.comDelveInsight Business Research, LLP: Global Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsightApril 26, 2024 | finanznachrichten.deCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD! November 22, 2024 | Desko Digital (Ad)Global Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsightApril 26, 2024 | tmcnet.comCinCor Pharma Inc.March 22, 2024 | thestreet.comPurdue Pharma to plead guilty in $8bn opioid settlementDecember 12, 2023 | bbc.comImpel Pharmaceuticals hit by another C-suite departureDecember 6, 2023 | bizjournals.comCatalyst Pharma's Finance Chief to Retire, Be Succeeded by Impel's CFODecember 4, 2023 | marketwatch.comSee More Headlines CINC Stock Analysis - Frequently Asked Questions When did CinCor Pharma IPO? CinCor Pharma (CINC) raised $176 million in an IPO on the week of November 7th 2022. The company issued 11,000,000 shares at $15.00-$17.00 per share. What other stocks do shareholders of CinCor Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that CinCor Pharma investors own include ARMOUR Residential REIT (ARR), AstraZeneca (AZN), AGNC Investment (AGNC), Amgen (AMGN), Broadcom (AVGO), Costco Wholesale (COST) and Cisco Systems (CSCO). Company Calendar Today11/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CINC CUSIPN/A CIK1868734 Webwww.cincor.com Phone844-531-1834FaxN/AEmployees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($17.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.03% Return on Assets-27.21% Debt Debt-to-Equity RatioN/A Current Ratio51.96 Quick Ratio51.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.74) per share Price / Book-16.70Miscellaneous Outstanding Shares43,760,000Free Float36,937,000Market Cap$1.27 billion OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:CINC) was last updated on 11/22/2024 by MarketBeat.com Staff From Our PartnersBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredTrump Won, But Can He Save Your 401(k)?Trump Won, But Your Savings Are Still In Danger It's the ONLY playbook that shows you how to fortify your f...Priority Gold | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CinCor Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CinCor Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
